subcutaneous injection – Communicable Diseases Research

Efficacy and safety of a single dose of casirivimab and imdevimab for the prevention of COVID-19 over an 8-month period: a randomised, double-blind, placebo-controlled trial

Randomized Controlled Trial

Published on 2022-07-052022-10-05
Journal: The Lancet. Infectious Diseases [Category] COVID19(2023년), SARS, 변종, 임상, 진단,

Estimated Health Outcomes and Costs of COVID-19 Prophylaxis With Monoclonal Antibodies Among Unvaccinated Household Contacts in the US

미국에서 백신 접종을 하지 않은 가족 중 단클론 항체를 사용한 COVID-19 예방의 예상 건강 결과 및 비용

Randomized Controlled Trial

Published on 2022-04-012022-09-11
Journal: JAMA Network Open [Category] COVID19(2023년), SARS, 변종, 임상, 진단,

[키워드] Administered age Casirivimab complementary confirmed COVID-19 case Contact Coverage COVID-19 COVID-19 case COVID-19 infection COVID-19 infections COVID-19 pandemic COVID-19 vaccination death deaths disrupt effective vaccine Effective vaccines eligible Estimated Ethnicity exposure to Health health system Hospitalization hospitalizations household household contact Imdevimab IMPROVE individual Infection intensity mAb mAbs monoclonal antibodies monoclonal antibody Older outcome Postexposure Prophylaxis Probability public health randomized clinical trial reduce reduce costs Sex subcutaneous injection subcutaneous injections susceptible symptomatic infection symptomatic infections threshold thresholds Transmission Vaccination Status Vaccine variant of SARS-CoV-2
[DOI] 10.1001/jamanetworkopen.2022.8632 PMC 바로가기 [Article Type] Randomized Controlled Trial

Rationale and design of a study to assess the safety and efficacy of rNAPc2 in COVID-19: the Phase 2b ASPEN-COVID-19 trial

Randomized Controlled Trial

Published on 2022-04-012022-10-05
Journal: American heart journal [Category] COVID19(2023년), SARS, 바이오마커, 임상,

[키워드] Anticoagulant appear assigned baseline bleeding blinded clinically Coagulation Coagulopathy Complete Concentration contribute COVID-19 D-dimer D-dimer level D-dimer levels Day discharge dose dose ranging Effect Efficacy elevated Endpoint Enrollment evaluate hospitalized COVID-19 patient IMPROVE in viral Infection Inflammation inflammatory signaling inhibitor Interaction limit Local nematode Open-label outcome outcomes participant patients hospitalized phase primary efficacy endpoint randomization Randomized Randomly rationale stratified subcutaneous injection Therapeutic approach therapeutic target thrombosis tissue Tissue Factor Trial viral propagation with COVID-19
[DOI] 10.1016/j.ahj.2021.12.010 PMC 바로가기 [Article Type] Randomized Controlled Trial

Subcutaneous sarilumab for the treatment of hospitalized patients with moderate to severe COVID19 disease: A pragmatic, embedded randomized clinical trial

중등도 내지 중증 CovID19 질병을 가진 입원 환자의 치료를위한 피하 Sarilumab : 실용적이고 임베디드 무작위 임상 시험

Randomized Controlled Trial

Published on 2022-02-252022-09-10
Journal: PLoS ONE [Category] 임상, 진단, 치료제,

[키워드] adaptive added addition adopted anti-IL-6R Anti-inflammatory drugs antibody Antiviral Arm benefit clinical criteria Clinical management contribute Controlled trial COVID-19 COVID-19 disease COVID19 Data monitoring committee death Dexamethasone diagnostic diagnostic test dose Effectiveness EHR Electronic health record Eligible patients evaluated event Health health record hospitalized COVID-19 patients hospitalized patient IL-6R Importance include information initial Inpatient Inpatients intubation majority measure mechanical ventilation moderate moderate to severe numbers of patient occurred Open-label outcome participant Patient patients hospitalized positive Pragmatic primary endpoint Primary outcome Probability randomization Randomized randomized clinical trial randomized trial Remdesivir respiratory respiratory compromise Result sarilumab SARS-CoV-2 setting severe COVID-19 severe COVID-19 disease Standard of care Subcutaneous subcutaneous injection the primary endpoint Treatment Trial was increased
[DOI] 10.1371/journal.pone.0263591 PMC 바로가기 [Article Type] Randomized Controlled Trial

Intravenous veterinary ivermectin in a COVID-19 patient causing neurotoxicity

Case report

Published on 2022-02-072022-10-05
Journal: IDCases [Category] 신약개발,

Translational studies of adrenomedullin and related peptides regarding cardiovascular diseases

Reviews

Published on 2022-01-062022-10-05
Journal: Hypertension research : official journal of the Ja [Category] 바이오마커,

Comprehensive engineering of a therapeutic neutralizing antibody targeting SARS-CoV-2 spike protein to neutralize escape variants

탈출 변이체를 중화하기 위해 SARS-CoV-2 스파이크 단백질을 표적으로 하는 치료 중화 항체의 포괄적 엔지니어링

Article

Published on 2022-01-012022-09-11
Journal: mAbs [Category] SARS, 변종, 진단,

P-130: The impact of COVID-19 on the treatment regimens of myeloma and AL amyloidosis patients

Conference abstract

Published on 2021-10-012022-10-05
Journal: Clinical lymphoma, myeloma & leukemia [Category] 치료법,

[키워드] administration amyloidosis Belgium Bone marrow Care Cell changes in conducted COVID-19 COVID-19 pandemic diagnosed Diagnosis Europe examined finding focus Frequency General population Germany group hcp healthcare Healthcare provider healthcare services hospital Iceland injection invasive Medicine Myeloma negatively affected Netherland one patient pandemic participant Patient Poland positive preference receiving reported researcher Result Romania Safe Side-effects Spain study participant subcutaneous injection suggested switching tablets took place Treatment treatment regimen virus was reduced
[DOI] 10.1016/S2152-2650(21)02257-6 [Article Type] Conference abstract

Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19

코로나19 예방을 위한 피하 REGEN-COV 항체 조합

Randomized Controlled Trial

Published on 2021-09-232022-09-12
Journal: The New England Journal of Medicine [Category] MERS, SARS, 임상, 진단, 치료법,

[키워드] 1:1 acute respiratory syndrome Administered age assigned Asymptomatic Combination Contact coronavirus coronavirus disease death diagnosis of SARS-CoV-2 diagnostic dose efficacy end point enrolled high risk Hospitalization household contact Immunity Infection Local matching placebo monoclonal antibody participant Participants Placebo Prevent prevented randomization Randomly receive reduce reduced REGEN-COV Regeneron Pharmaceutical REGN-CoV2 resolution of symptom risk risk reduction SARS-CoV-2 SARS-COV-2 infection Seronegativity shown stratified Subcutaneous subcutaneous injection subsequent symptomatic symptomatic and asymptomatic symptomatic COVID-19 symptomatic disease symptomatic SARS-CoV-2 infection the median the placebo group toxic effect uninfected Viral load
[DOI] 10.1056/NEJMoa2109682 PMC 바로가기 [Article Type] Randomized Controlled Trial

Rhabdomyolysis Following Ad26.COV2.S COVID-19 Vaccination

Brief Report

Published on 2021-08-272022-10-28
Journal: Vaccines [Category] COVID-19,